Why Celebs and Athletes Are Embracing Blood Flow Restriction Training – menshealth.com

DO REPS OF any exercise with a challenging weight (something beyond 65 percent of your max) and the muscles youre working contract so tightly that they trap blood within them, preventing that blood from returning to your heart. This restriction of blood fatigues your muscles and leads to lactic acid buildup, which, eventually, pushes your body to adapt by building tougher, stronger muscles.

Read more
Market trends and outlook coupled with factors driving and restraining the growth of the CRISPR Genome Editing market – The Daily Chronicle

With 75 percent of current S&P 500 companies expected to disappear until 2027, according to research by McKinsey. The only constant in our world is changing, the pace of change has been expediting significantly over the past years, fueled by huge investments in technology and science, easier access to truly global markets, and a general cultural shift towards innovation among other key drivers are helping to rise of CRISPR Genome Editing market.

Read more
COVID is shifting the conversation about the medical application of CBD – Open Access Government

COVID-19 has spread around the planet, sending billions of people into lockdown as health services struggle to cope. The statistics are startling global cases stand at 23,139,628 and with a total death toll of 801,795 and new daily cases rising (John Hopkins University data 23 Aug 2020), the outbreak has thrown an unprecedented challenge to the world and its citizens

Read more
Merck’s KEYTRUDA (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk…

KENILWORTH, N.J., & BRUSSELS--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the European Organisation for Research and Treatment of Cancer (EORTC) today announced new and updated findings from the Phase 3 EORTC1325/KEYNOTE-054 trial evaluating KEYTRUDA, Mercks anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma. Late-breaking, first-time study results showed that with 3.5 years of follow-up, adjuvant KEYTRUDA met the key secondary endpoint of distant metastasis-free survival (DMFS), reducing the risk of distant metastasis or death by 40% versus placebo (HR=0.60 [95% CI, 0.49-0.73]; p 1 mm lymph node metastasis), IIIB and IIIC melanoma, with 3.5-year RFS rates of 59.8% for KEYTRUDA versus 41.4% for placebo (HR = 0.59 [95% CI, 0.49-0.70]; p 1 mm lymph node metastasis], IIIB and IIIC). The co-primary endpoints are RFS for all patients and RFS in patients whose tumors expressed PD-L1.

Read more